Jianmin Pharmaceutical Group Co Ltd Total Liabilities
Jianmin Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) has total liabilities worth CN¥1.92 Billion CNY (≈ $281.42 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 600976 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Jianmin Pharmaceutical Group Co Ltd (2001–2025)
Total liabilities of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025. This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Jianmin Pharmaceutical Group Co Ltd (600976) investment intensity to see how much of total assets are deployed in long-term investments.
Jianmin Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jianmin Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MFA Financial Inc
NYSE:MFA
|
USA | $11.88 Billion |
|
Tamar Petroleum Ltd
TA:TMRP
|
Israel | ILA757.70 Million |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
China | CN¥921.14 Million |
|
Shenzhen Minglida Precision Technology Co. Ltd.
SHE:301268
|
China | CN¥4.41 Billion |
|
HomeTrust Bancshares, Inc.
NASDAQ:HTB
|
USA | $3.99 Billion |
|
Nanjing Chemical Fibre Co Ltd
SHG:600889
|
China | CN¥893.26 Million |
|
Sheela Foam Limited
NSE:SFL
|
India | Rs18.57 Billion |
|
Marimaca Copper Corp.
AU:MC2
|
Australia | AU$7.25 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Jianmin Pharmaceutical Group Co Ltd asset portfolio.
Liquidity & Leverage Metrics
Jianmin Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Jianmin Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jianmin Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jianmin Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total liabilities of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.81 Billion ≈ $264.23 Million |
-1.18% |
| 2024-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
-4.40% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.71 Million |
+21.76% |
| 2022-12-31 | CN¥1.57 Billion ≈ $229.71 Million |
+24.85% |
| 2021-12-31 | CN¥1.26 Billion ≈ $183.99 Million |
+14.94% |
| 2020-12-31 | CN¥1.09 Billion ≈ $160.07 Million |
+51.80% |
| 2019-12-31 | CN¥720.63 Million ≈ $105.45 Million |
+24.87% |
| 2018-12-31 | CN¥577.11 Million ≈ $84.45 Million |
-29.34% |
| 2017-12-31 | CN¥816.71 Million ≈ $119.51 Million |
+5.18% |
| 2016-12-31 | CN¥776.45 Million ≈ $113.62 Million |
+28.40% |
| 2015-12-31 | CN¥604.72 Million ≈ $88.49 Million |
+11.00% |
| 2014-12-31 | CN¥544.79 Million ≈ $79.72 Million |
+7.90% |
| 2013-12-31 | CN¥504.92 Million ≈ $73.89 Million |
+41.08% |
| 2012-12-31 | CN¥357.90 Million ≈ $52.37 Million |
+22.87% |
| 2011-12-31 | CN¥291.28 Million ≈ $42.62 Million |
+27.32% |
| 2010-12-31 | CN¥228.78 Million ≈ $33.48 Million |
-51.91% |
| 2009-12-31 | CN¥475.79 Million ≈ $69.62 Million |
+19.61% |
| 2008-12-31 | CN¥397.80 Million ≈ $58.21 Million |
+178.04% |
| 2007-12-31 | CN¥143.07 Million ≈ $20.94 Million |
-49.83% |
| 2006-12-31 | CN¥285.18 Million ≈ $41.73 Million |
-5.36% |
| 2005-12-31 | CN¥301.33 Million ≈ $44.09 Million |
+37.36% |
| 2004-12-31 | CN¥219.38 Million ≈ $32.10 Million |
-9.46% |
| 2003-12-31 | CN¥242.31 Million ≈ $35.46 Million |
+25.34% |
| 2002-12-31 | CN¥193.32 Million ≈ $28.29 Million |
+17.27% |
| 2001-12-31 | CN¥164.85 Million ≈ $24.12 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.